Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-64-5
Name of the chemical
polyethyleneglycol sorbitan monolaurate
Concentration
N/A
General Information
Version
5.0
Revision date
2009-08-19
Product name
Avastin
Chemical name
Recombinant humanized monoclonal IgG1 antibody to vascular endothelial growth factor (VEGF)
Icons in SDS
Company Information
company name
Genentech, Inc
Section 2
SECTION 2: Hazards identification
Emergency Overview Avastin® derives its therapeutic benefit from a monoclonal antibody (bevacizumab) that is not well absorbed by inhalation or by contact with eyes, skin, or mucous membranes. Adverse health effects have been observed in patients following intravenous (IV) infusion of theraputic doses for the treatment of numerous types of cancer. Although the health effects of occupational exposure to this product are not fully known or characterized, no adverse effects are anticipated as a result of occupational or incidental exposure. This product is a clear to slightly opalescent, colorless to pale brown liquid. For more product information see Section 11 or visit www.gene.com.
Principle Routes of Exposure
Direct contact with eyes, skin, or mucous membranes is the possible primary route of occupational exposure. No adverse health effects through these routes are expected to occur in occupational exposure conditions due to the large size of bevacizumab (a full length monoclonal antibody with a molecular weight of ~149,000 daltons) and its poor potential for absorption.
